NRIX Stock — Nurix Therapeutics Inc.: Cash, EV, Pipeline

Share price

$25.44

Market cap

$2,640.2M

Cash

$443.5M

Enterprise value

$2,196.7M

Balance sheet

Cash	$443.5M
Debt	$0.0M
Net cash	$443.5M
Enterprise value	$2,196.7M
Basic shares	103.7M shares
Fully diluted shares	120.5M shares
Fully diluted market cap	$3,066.7M
Cash per share	$4.28

Cash figures as of 2026-05-31. Database snapshot: 2026-09-21.

Price history

Loading NRIX daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Oct 12 - Nov 23	NX-1607	Phase 1	Ovarian Cancer, Epithelial; Gastric Cancer; GastroEsophageal Junction (GEJ) Cancer	—
Feb 12 - Mar 26	NX-5948	Phase 1	Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL); Diffuse Large B Cell Lymphoma (DLBCL)	—
Feb 12 - Mar 25	NX-5948	Phase 2	Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL)	—
Nov 12 - Dec 24	NX-5948	Phase 3	B-cell Lymphoma; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma	—
Jun 12 - Jul 24	NX-5948	Phase 2	B-cell Lymphoma; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

bexobrutideg

Phase 2 · Active Modality: protein degrader (small molecule)

Aliases NX-5948

Target BTK

Indications

Relapsed/refractory chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL) (Phase 2)
Waldenstrom's macroglobulinemia (WM) (Stage not disclosed)

Status note BTK degrader. Phase 2 study in R/R CLL patients having failed three prior lines (cBTKi, BCL2i, ncBTKi) commenced Oct 2025. FDA Fast Track designated for R/R CLL/SLL (Jan 2024) and WM (Dec 2024); EMA PRIME designated for CLL/SLL (Nov 2024).

zelebrudomide

Phase 1 · Active Modality: protein degrader (small molecule)

Aliases NX-2127

Target BTK, IKZF1, IKZF3

Indications

Relapsed/refractory B-cell malignancies (Phase 1)

Status note Dual degrader of BTK and IKZF1/IKZF3. Phase 1a/1b dose-escalation and cohort expansion in R/R B-cell malignancies; enrollment paused in 2023 on partial clinical hold and recommenced Aug 2024. Dose escalation ongoing.

NX-1607

Phase 1 · Active Modality: small molecule inhibitor

Target CBL-B

Indications

Oncology (multiple indications) (Phase 1)

Status note CBL-B inhibitor. Phase 1a/1b dose-escalation and cohort expansion in a range of oncology indications. Awarded UK MHRA Innovation Passport in 2022.

NX-0479

Stage not disclosed · Active Modality: protein degrader (small molecule)

Aliases GS-6791

Target IRAK4

Partnerships Gilead Sciences (global strategic collaboration; Gilead licensed the IRAK4 degrader program)

Indications

not disclosed (Stage not disclosed)

Status note Clinical-stage IRAK4 degrader under the Gilead collaboration; Sanofi and Pfizer also hold protein-degradation collaborations (preclinical stage, targets undisclosed).

Per-asset detail extracted from the 10-Q filed 2026-07-09. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	NX-5948
Lead indication	B-cell Lymphoma
Lead phase	Phase 3
Active trials	6

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07516093	Phase 3	Recruiting	Sponsor	NRIX	—	B-cell Lymphoma; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma	—
NCT07221500	Phase 2	Recruiting	Sponsor	NRIX	—	Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL)	—
NCT07520006	Phase 2	Recruiting	Sponsor	NRIX	—	B-cell Lymphoma; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma	—
NCT05131022	Phase 1	Recruiting	Sponsor	NRIX	—	Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL); Diffuse Large B Cell Lymphoma (DLBCL)	—
NCT04830137	Phase 1	Recruiting	Sponsor	NRIX	—	Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL); Waldenstrom Macroglobulinemia (WM)	—
NCT05107674	Phase 1	Recruiting	Sponsor	NRIX	—	Ovarian Cancer, Epithelial; Gastric Cancer; GastroEsophageal Junction (GEJ) Cancer	—

Sponsor-matched active trials from ClinicalTrials.gov (6 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 6 active trials for Nurix Therapeutics, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Baker Bros. Advisors	4,658,556	no change	0.57%	2026-08-14
Braidwell LP	1,286,769	-463,997	1.15%	2026-08-14
ADAR1 Capital Management	313,236	+257,166	0.36%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

NRIX — Nurix Therapeutics Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders